A study testing whether a GLP-1 medicine from University of Chicago, semaglutide, can help with weight.
What this means for you
- Who can join
- Adults 18 to 75, have obesity or are overweight, BMI 30+.
- What you take
- semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 3.2 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Overweight or Obesity. Also studied in: Atrial Fibrillation.
Full scientific study title: Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation.
Who can join
Adults 18 to 75, have obesity or are overweight, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age 18-75 years
- BMI greater than or equal to 30 kg/m2
- Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)
- Ability to provide informed consent before any trial-related activities.
- Patients with type 2 diabetes mellitus (T2DM) will be included:
Key exclusion criteria
- Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening
- Current antiobesity medication use or use within the last 90 days prior to screening
- A self-reported change in body weight of > 5 kg (11 lb.) within 30 days before screening
- History of bariatric surgery
- History of type I diabetes mellitus
Where this study is enrolling
This trial has 2 sites across 2 states. Contact a site coordinator directly to start screening.
Arizona1 site
- The University of Arizona College of Medicine- PhoenixPhoenix, Arizona
Illinois1 site
- University of ChicagoChicago, Illinois
Timeline
Started enrolling: 2025-04-14. Expected completion: 2028-06. Last updated on ClinicalTrials.gov: 2025-11-14.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
